文献速递糖尿病肥胖与代谢综合征

减肥手术后七年随访中的糖尿病缓解状态:纵向评估减肥手术研究

Diabetes Remission Status During Seven-year Follow-up of the Longitudinal Assessment of Bariatric Surgery Study.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

结果显示RYGB后糖尿病缓解率57%,LAGB后22.5%,且缓解与年轻、糖尿病病程短、C肽水平高、β细胞功能保留及术后体重下降多相关。

要点

  • RYGB术后7年糖尿病缓解率57%,LAGB为22.5%。
  • 年轻、糖尿病病程短、C肽高、HOMA-%B高、胰岛素用量低者缓解率更高。
  • 控制体重下降后,RYGB的糖尿病缓解率仍比LAGB高近4倍。

核心结论

  • 减肥手术后长期糖尿病缓解在诊断后尽早手术、糖尿病药物负担低且β细胞功能保留时更可能实现。
  • RYGB术后糖尿病缓解率高于LAGB,且独立于体重下降,提示体重以外机制贡献于β细胞功能改善。

研究设计与样本

  • 观察性队列研究,2006至2009年招募的严重肥胖成人,每年随访至术后7年。
  • 共2256例参与者,其中827例有基线及至少1次随访的已知糖尿病状态。
  • 干预为Roux-en-Y胃旁路术(RYGB)或腹腔镜可调节胃束带术(LAGB)。

主要发现

  • 糖尿病缓解率:RYGB后57%(完全缓解46%,部分缓解11%),LAGB后22.5%(完全缓解16.9%,部分缓解5.6%)。
  • 两种术后,年轻、糖尿病病程短、基线C肽高、HOMA-%B高、胰岛素用量低及术后体重下降多者缓解率更高。
  • LAGB后HOMA-IR降低与缓解可能性增加相关,RYGB后HOMA-%B升高预测缓解。
  • 控制体重下降后,RYGB的糖尿病缓解率仍比LAGB高近4倍。

关键数值与推荐

  • 糖尿病缓解定义为完全缓解或部分缓解,具体标准未在摘要中详述。
  • 基线特征与缓解的关联:年龄、糖尿病病程、C肽、HOMA-%B、胰岛素使用、术后体重下降。

临床怎么用

  • 对于严重肥胖合并糖尿病患者,考虑在糖尿病病程较短、β细胞功能尚存且胰岛素用量较低时行减肥手术。
  • RYGB可能比LAGB提供更高的长期糖尿病缓解机会,且部分获益独立于体重下降。

局限性

  • 观察性队列设计,可能存在残余混杂。
  • 仅827例有基线及至少1次随访的糖尿病状态数据,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Few studies have examined the clinical characteristics that predict durable, long-term diabetes remission after bariatric surgery. OBJECTIVE: To compare diabetes prevalence and remission rates during 7-year follow-up after Roux-en-Y gastric bypass (RYGB) and laparoscopic gastric banding (LAGB). DESIGN: An observational cohort of adults with severe obesity recruited between 2006 and 2009 who completed annual research assessments for up to 7 years after RYGB or LAGB. SETTING: Ten US hospitals. PARTICIPANTS: A total sample of 2256 participants, 827 with known diabetes status at both baseline and at least 1 follow-up visit. INTERVENTIONS: Roux-en-Y gastric bypass or LAGB. MAIN OUTCOME MEASURES: Diabetes rates and associations of patient characteristics with remission status. RESULTS: Diabetes remission occurred in 57% (46% complete, 11% partial) after RYGB and 22.5% (16.9% complete, 5.6% partial) after LAGB. Following both procedures, remission was greater in younger participants and those with shorter diabetes duration, higher C-peptide levels, higher homeostatic model assessment of β-cell function (HOMA %B), and lower insulin usage at baseline, and with greater postsurgical weight loss. After LAGB, reduced HOMA insulin resistance (IR) was associated with a greater likelihood of diabetes remission, whereas increased HOMA-%B predicted remission after RYGB. Controlling for weight lost, diabetes remission remained nearly 4-fold higher compared with LAGB. CONCLUSIONS: Durable, long-term diabetes remission following bariatric surgery is more likely when performed soon after diagnosis when diabetes medication burden is low and beta-cell function is preserved. A greater weight-independent likelihood of diabetes remission after RYGB than LAGB suggests mechanisms beyond weight loss contribute to improved beta-cell function after RYGB.Trial Registration clinicaltrials.gov Identifier: NCT00465829.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Purnell JQ, Dewey EN, Laferrère B, et al. Diabetes Remission Status During Seven-year Follow-up of the Longitudinal Assessment of Bariatric Surgery Study. J Clin Endocrinol Metab. 2021. PMID: 33270130. doi:10.1210/clinem/dgaa849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。